source
- Kodiak Sciences' Phase 3 eye drug data beats Regeneron’s Eylea, shares doubleKodiak Sciences reported that its two experimental treatments for macular degeneration met the primary endpoints in a Phase 3 trial that directly compared them with Regeneron’s Eylea. The data show…
- Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMDKodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneratio…